Ionis Pharmaceuticals, Inc. announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca’s eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy, a debilitating and potentially fatal disease that leads to peripheral nerve damage and motor disability.
